SJS. Claiborne Johnston

S. Claiborne Johnston

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


S. Claiborne Johnston has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Daryl R. Gress

    From the Neurovascular Service, Department of Neurology (S.C.J., S.Z., D.R.G.), and Institute of Health Policy Studies (A.D.), University of California at San Francisco; and the Department of Anesthesia, Columbia University Medical Center, New York, NY (M.F.B.).

    4 shared publications
  • R. Adams Dudley

    From the Neurovascular Service, Department of Neurology (S.C.J., S.Z., D.R.G.), and Institute of Health Policy Studies (A.D.), University of California at San Francisco; and the Department of Anesthesia, Columbia University Medical Center, New York, NY (M.F.B.).

    2 shared publications
  • Warren S. Browner

    From Neurovascular Service, Department of Neurology (S.C.J., C.M.); Division of Vascular Surgery, Department of Surgery (L.M.M.); Department of Neurological Surgery (M.T.L.); and Division of Infectious Diseases, Department of Medicine (D.D.), University of California, San Francisco; California Pacific Medical Center Research Institute, San Francisco (W.S.B.); and Children’s Hospital of Oakland Research Institute, Oakland, Calif (D.D.).

    2 shared publications
  • Andrew N. Brown

    From the Neurovascular Service, Department of Neurology, University of California, San Francisco, Calif (S.C.J., L.H.F., L.A.G., W.S.S., A.N.B.), and the Department of Neurology, Yale University School of Medicine, New Haven, Conn (L.M.B., J.H.L.).

    1 shared publication
  • Caroline Morris

    From Neurovascular Service, Department of Neurology (S.C.J., C.M.); Division of Vascular Surgery, Department of Surgery (L.M.M.); Department of Neurological Surgery (M.T.L.); and Division of Infectious Diseases, Department of Medicine (D.D.), University of California, San Francisco; California Pacific Medical Center Research Institute, San Francisco (W.S.B.); and Children’s Hospital of Oakland Research Institute, Oakland, Calif (D.D.).

    1 shared publication
  • Deborah Dean

    From Neurovascular Service, Department of Neurology (S.C.J., C.M.); Division of Vascular Surgery, Department of Surgery (L.M.M.); Department of Neurological Surgery (M.T.L.); and Division of Infectious Diseases, Department of Medicine (D.D.), University of California, San Francisco; California Pacific Medical Center Research Institute, San Francisco (W.S.B.); and Children’s Hospital of Oakland Research Institute, Oakland, Calif (D.D.).

    1 shared publication

Latest Publications

  • Chronic dyspnea and hyperventilation in an awake patient with small subcortical infarcts

    by S. Claiborne Johnston, Vineeta Singh, Henry J. Ralston, Warren M. Gold

    A 79-year-old woman presented with chronic dyspnea and hyperventilation. There was no evidence of pulmonary disease. Hyperventilation persisted during sleep and after high-dose administration of a narcotic. A head MRI revealed bilateral medial thalamic infarctions. Central neurogenic hyperventilation was diagnosed in this alert patient. The case may illustrate a role for the thalamus in regulating ventilation, but another small infarct not visible on MRI also could be responsible.


  • C-Reactive Protein Levels and Viable Chlamydia pneumoniae in Carotid Artery Atherosclerosis

    by S. Claiborne Johnston, Louis M. Messina, Warren S. Browner, Michael T. Lawton, Caroline Morris, Deborah Dean

    Background and Purpose — An elevated serum level of C-reactive protein, an inflammatory marker, is an independent predictor of stroke and coronary artery disease. To determine whether chronic infection with Chlamydia pneumoniae , which has been identified in atherosclerotic plaques, is responsible for systemic inflammation, we studied the association between serum C-reactive protein levels and infection of carotid artery atherosclerotic plaque with viable C pneumoniae . Methods — Serum C-reactive protein levels were obtained before endarterectomy for carotid artery stenosis. Plaques were tested for C pneumoniae mRNA, an indicator of viability, and DNA by polymerase chain reaction of DNA and cDNA, respectively. Results — Forty-eight samples were studied, of which 18 (38%; 95% CI, 23 to 50) were infected with viable C pneumoniae as evidenced by isolated chlamydial mRNA. All 18 of these samples, plus 1 additional sample, were positive for chlamydial DNA. Serum C-reactive protein levels were higher in those with viable C pneumoniae compared with those without infection (median, 8 mg/L versus undetectable; P =0.045 by Wilcoxon rank-sum test). In multivariable models, the only independent predictor of the presence of viable C pneumoniae was a detectable C-reactive protein level (odds ratio, 4.2; 95% CI, 1.1 to 17; P =0.04). Conclusions — Viable C pneumoniae are present in a substantial portion of carotid artery atherosclerotic plaques and are associated with increased serum C-reactive protein levels. These findings may explain the link between elevated C-reactive protein levels and the risk of cardiovascular disease and stroke but should be reproduced in a larger cohort.


  • Characteristics of Academic Medical Centers and Ischemic Stroke Outcomes

    by Leslie Allison Gillum, S. Claiborne Johnston

    Background and Purpose — Data supporting the efficacy of stroke center characteristics are limited. Methods — A questionnaire detailing stroke treatment practices was sent to 42 academic medical centers in the University Health Systems Consortium. In-hospital mortality of all emergency department admissions for ischemic stroke at these institutions was evaluated in a database of discharge abstracts during 1997–1999. Institutional characteristics were evaluated as predictors of in-hospital mortality after adjustment for age, sex, race, hospital treatment volume of ischemic stroke, and admission status (emergent, urgent, elective). Length of stay (LOS), total hospital charges, and frequency of tissue plasminogen activator (tPA) administration were evaluated as secondary outcomes. We used a multivariable method called generalized estimating equations, which broadens confidence intervals to adjust for clustering of variables at institutions. Results — Thirty-two institutions completed the questionnaire, and 29 of these were included in the database of discharge abstracts. In-hospital deaths occurred in 758 (7.0%) of the 10 880 ischemic stroke patients admitted through the emergency department. In-hospital deaths were less frequent at hospitals with a vascular neurologist (odds ratio [OR] 0.51; 95% CI, 0.36 to 0.74; P P =0.004). There was a trend toward fewer deaths at hospitals with a dedicated stroke team available by pager (OR, 0.76; 95% CI, 0.56 to 1.04; P =0.09). The presence of a dedicated neurological intensive care unit, stroke unit, and written clinical pathway for stroke were not significantly associated with in-hospital death. LOS was shorter at hospitals with a vascular neurologist ( P =0.01). Conclusions — Academic medical centers with a vascular neurologist and those with written guidelines limiting tPA administration to neurologists had lower rates of in-hospital mortality for ischemic stroke patients.


  • Open Access

    Identifying Confounding by Indication through Blinded Prospective Review

    by S. Claiborne Johnston

    Confounding by indication is a relentless threat to validity in observational studies of treatment effects. Multivariable models allow adjustment for known and readily measurable prognostic factors, but they may incompletely or inaccurately represent the underlying overall perceived risk of treatment. To incorporate practitioners' judgments about treatment indication and preprocedural prognosis into an observational study of cerebral aneurysm treatments, the author and colleagues presented patient characteristics and radiographic images from 179 aneurysm cases (University of California, San Francisco, 1990–1997) to panels of practitioners who were blinded as to actual treatment selection and outcome. In this way, the review process was designed to recreate the presentation of information in a prospective study. Judgments about inclusion and prognosis were reproducible. Perceived prognosis correlated with complication rates and provided information not present in a multivariable model including all available clinical characteristics. The association between treatment modality and outcome was examined while stratifying and adjusting for differences in perceived prognosis. Blinded prospective review may provide an unbiased observational study design with which to define a cohort that could have received any of the treatments being compared and to measure and adjust for overall perceived procedural risk.


  • Utilization of Intravenous Tissue-Type Plasminogen Activator for Ischemic Stroke at Academic Medical Centers

    by S. Claiborne Johnston, Lawrence H. Fung, Leslie A. Gillum, Wade S. Smith, Lawrence M. Brass, Judith H. Lichtman, Andrew N. Brown

    Background and Purpose —We sought to measure the overall rate of usage of tissue-type plasminogen activator (tPA) for ischemic stroke at academic medical centers, and to determine whether ethnicity was associated with usage. Methods —Between June and December 1999, 42 academic medical centers in the United States each identified 30 consecutive ischemic stroke cases. Medical records were reviewed and information on demographics, medical history, and treatment were abstracted. Rates of tPA use were compared for African Americans and whites in univariate analysis and after adjustment for age, gender, stroke severity, and type of medical insurance with multivariable logistic regression. Results —Complete information was available for 1195 ischemic stroke patients; 788 were whites and 285 were African Americans. Overall, 49 patients (4.1%) received tPA. In the subgroup of 189 patients without a documented contraindication to therapy, 39 (20.6%) received tPA. Ten (20%) of those receiving tPA had documented contraindication.African Americans were one fifth as likely to receive tPA as whites (1.1% African Americans versus 5.3%; P =0.001), and the difference persisted after adjustment (OR 0.21, 95% CI 0.06 to 0.68; P =0.01). When comparison was restricted to those without a documented contraindication to tPA, the difference remained significant (OR 0.24, 95% CI 0.06 to 0.93; P =0.04).Medical insurance type was independently associated with tPA treatment. After adjustment for ethnicity and other demographic characteristics, those with Medicaid or no insurance were one ninth as likely to receive tPA as those with private medical insurance (OR 0.11, 95% CI 0.02 to 0.17; P =0.003). Conclusions —tPA is used infrequently for ischemic stroke at US academic medical centers, even among qualifying candidates. African Americans are significantly less likely to receive tPA for ischemic stroke. Contraindications to treatment do not appear to account for the difference.


  • Treatment of Unruptured Cerebral Aneurysms in California

    by S. Claiborne Johnston, Shoujun Zhao, R. Adams Dudley, Mitchell F. Berman, Daryl R. Gress

    Background and Purpose —The impact of endovascular therapy on treatment outcomes of unruptured cerebral aneurysms has not been studied in a defined geographic area. Methods —All primary diagnoses of unruptured aneurysms were retrieved from a statewide database of hospital discharges in California from January 1990 through December 1998. Admissions for initial treatment and all follow-up care were combined to reflect the entire course of therapy. An adverse outcome was defined as an in-hospital death or discharge to nursing home or rehabilitation hospital at any point during the treatment course. Multivariable analyses were performed with generalized estimating equations with adjustment for age, sex, ethnicity, source of admission, year of treatment, hospital volume, and clustering of observations at institutions. Results —A total of 2069 patients were treated for unruptured aneurysms. Adverse outcomes were more frequent in the 1699 patients treated with surgery (25%) than in those treated with endovascular therapy (10%; P P P P =0.003), and the difference remained significant after adjustment (odds ratio, 6.3; 95% CI, 3.5 to 11.4; P P Conclusions —In California, endovascular therapy of unruptured aneurysms is associated with less risk of adverse outcomes and in-hospital death, lower hospital charges, and shorter hospital stays compared with surgery. Differences between therapies became more distinct through the years. Uncontrolled differences in prognosis of patients receiving endovascular therapy and surgery cannot be ruled out in this study of discharge abstracts.


  • Top Cited Papers
    Open Access

    Short-term Prognosis After Emergency Department Diagnosis of TIA

    by S. Claiborne Johnston, Daryl R. Gress, Warren S. Browner, Stephen Sidney

    Transient ischemic attacks (TIAs) are common1: approximately 300,000 TIAs occur each year in the United States based on recent estimates of stroke incidence.2,3 A recent survey suggested a much higher incidence, with 1 in 15 of those older than age 65 years reporting a history of TIA.4 About 15% of patients experiencing stroke report a history of TIA.5 Effective prevention of subsequent stroke in patients with TIAs could significantly reduce the overall stroke incidence.6


  • Effect of Endovascular Services and Hospital Volume on Cerebral Aneurysm Treatment Outcomes

    by S. Claiborne Johnston

    Background and Purpose —Endovascular coil embolization and angioplasty for cerebral vasospasm are offered by some centers for the treatment of unruptured and ruptured cerebral aneurysms. Whether the availability of these therapies improves outcomes at these institutions has not been evaluated. Methods —We assessed institutional factors in the outcomes of patients treated for cerebral aneurysms in the academic medical centers of the University Health Systems Consortium. In-hospital deaths (primary outcome), length of stay, and hospital charges were evaluated in multivariable models adjusted for age, sex, race, admission source, and admission status. Results —There were 2623 unruptured and 9534 ruptured aneurysm cases treated at 70 centers in the University Health Systems Consortium hospital discharge database during 1994–1997. Patients treated at institutions that more frequently used coil embolization were less likely to die in the hospital (relative risks [RRs] for every 10% of endovascular-treated cases: ruptured aneurysms: RR, 0.91; 95% CI, 0.86 to 0.96; P =0.001; unruptured aneurysms: RR, 0.84; 95% CI, 0.78 to 0.91; P P =0.03). Hospital treatment volume was not independently associated with in-hospital death. Conclusions —-Patients treated for cerebral aneurysms at institutions offering endovascular services have lower rates of in-hospital mortality. Whether this is due to improved outcomes with endovascular therapy or is a marker for other aspects of multidisciplinary care cannot be answered in this analysis.


  • Surgical and endovascular treatment of unruptured cerebral aneurysms at university hospitals

    by S. Claiborne Johnston, R. Adams Dudley, Daryl R. Gress, Linda Ono

    Objective: To compare complications of surgical clipping and coil embolization in the treatment of unruptured aneurysms. Background: Surgical clipping has been the preferred treatment for unruptured cerebral aneurysms but endovascular coil embolization is an increasingly employed alternative. No direct comparisons of the techniques are available to guide clinical decision making. Methods: We performed a cohort study of patients treated for unruptured cerebral aneurysms at 60 university hospitals from January 1994 through June 1997 using the University HealthSystem Consortium database. The database was validated by chart review from one of the participant universities. The main outcome measures were in-hospital mortality and adverse outcomes, defined as in-hospital deaths and discharges to nursing homes or rehabilitation hospitals. Results: The primary treatment modality was surgical in 2,357 cases and endovascular in 255 cases. Adverse outcomes were significantly more common in surgical cases (18.5%) compared to endovascular cases (10.6%) (p = 0.002), and the difference was not altered after adjusting for age, sex, race, transfer admissions, emergency room admissions, and year of treatment (odds ratio [OR] 2.1, 95% confidence interval [CI] 1.4 to 3.3; p = 0.001). In-hospital mortality was also increased in surgical cases (2.3% versus 0.4%; p = 0.039), but the difference was not significant in the multivariable model (OR 6.3, 95% CI 0.9 to 46.1; p = 0.07). Length of stay and hospital charges were significantly greater for surgical cases (p < 0.0001 for each), and these differences were not affected by risk adjustment. Conclusion: Endovascular coil embolization resulted in fewer adverse outcomes than surgery for unruptured cerebral aneurysms treated at the university hospitals studied. Although these results should be seen as preliminary, the magnitude of difference and current predominance of surgery appear to justify a randomized trial.